Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Income from Non-Controlling Interests: 2014-2015

Historic Income from Non-Controlling Interests for Ligand Pharmaceuticals (LGND) over the last 1 years, with Jun 2015 value amounting to -$1.5 million.

  • Ligand Pharmaceuticals' Income from Non-Controlling Interests fell 405.59% to -$1.5 million in Q2 2015 from the same period last year, while for Jun 2015 it was -$3.2 million, marking a year-over-year change of. This contributed to the annual value of $2.4 million for FY2015, which is 310.25% up from last year.
  • Ligand Pharmaceuticals' Income from Non-Controlling Interests amounted to -$1.5 million in Q2 2015, which was down 82.33% from -$843,000 recorded in Q1 2015.
  • Ligand Pharmaceuticals' 5-year Income from Non-Controlling Interests high stood at -$304,000 for Q2 2014, and its period low was -$1.5 million during Q2 2015.
  • Over the past 2 years, Ligand Pharmaceuticals' median Income from Non-Controlling Interests value was -$503,000 (recorded in 2014), while the average stood at -$702,400.
  • Data for Ligand Pharmaceuticals' Income from Non-Controlling Interests shows a maximum YoY slumped of 405.59% (in 2015) over the last 5 years.
  • Over the past 2 years, Ligand Pharmaceuticals' Income from Non-Controlling Interests (Quarterly) stood at -$325,000 in 2014, then crashed by 405.59% to -$1.5 million in 2015.
  • Its last three reported values are -$1.5 million in Q2 2015, -$843,000 for Q1 2015, and -$325,000 during Q4 2014.